This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Williams, S. B. Articles by Ferguson, J. J. Search for Related Content PubMed Articles by Williams, S. B. Articles by Ferguson, J. J. Related Collections Congestive Restenosis Clinical Studies Acute coronary syndromes CV surgery: coronary artery disease

(Circulation. 2002;106:e211.)
© 2002 American Heart Association, Inc.

ESC Meeting Highlights

Meeting Highlights

Highlights of the 24th Congress of the European Society of Cardiology

Stephen B. Williams, MD, MPH; James J. Ferguson, MD

From St Luke’s Episcopal Hospital, Texas Heart Institute, Houston, Tex.

Correspondence to James J. Ferguson, MD, Cardiology Research, Texas Heart Institute/St Luke’s Episcopal Hospital, 6720 Bertner Ave, MC 1-191, Houston, TX 77030. E-mail jferguson@heart.thi.tmc.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Acute Coronary Syndromes

MAGnesium In Coronaries (MAGIC)
Presenter:
Elliot M. Antman, MD (Brigham and Women’s Hospital, Boston, Mass)

Purpose:
To examine the effect of early administration of magnesium therapy in high-risk patients with ST-elevation acute myocardial infarction (AMI).

Study:
High-risk patients presenting with ST-elevation AMI were enrolled within 6 hours of presentation and included both those who were >65 years of age and eligible for reperfusion (Stratum I) as well as those in all age groups who were eligible for reperfusion (Stratum II). Cardiogenic shock, high-grade AV block, and severe renal failure were exclusion criteria. The patients were randomized in double-blinded fashion to receive either magnesium (n=3110, 2-g bolus over 15 minutes followed by an infusion of 17 g over 24 hours) or (volume-matched) placebo (n=3098). The primary end point was 30-day mortality.

Results:
The incidence of death by 30 days was not significantly different between the magnesium-treated (n=475, 15%) and placebo-treated (n=472, 15%) patients with an odds ratio of 1.0 (CI 0.9 to 1.2, P=0.96). Similarly, there was no difference with magnesium-therapy in the secondary end points of defibrillation (5% in both groups), pacemaker requirement (2% in both groups), or requisite therapies for congestive heart failure (18% vs 19%).

Summary:
The early administration of magnesium in high-risk patients with ST-elevation myocardial infarction has no benefit on 30-day mortality or on secondary outcomes of arrhythmia or congestive heart failure. No subgroups showed benefit in this study. There appears to be no indication for the routine administration of magnesium to patients with ST-elevation myocardial infarction at any level of risk. However, as . . . [Full Text of this Article]